Companies / Pharma
Alcon Pays $550 Million for Neurotech and ENCELTO, the Only Approved Treatment for MacTel Type 2
The completed acquisition hands Alcon the first and only FDA-approved therapy for MacTel Type 2 and the cell-therapy platform behind it, with more to pay if commercial milestones are reached.